Results in patients with relapsed APL after treatment with As4S4
| Patient no./age, y/sex . | Days to HCR . | Total As4S4 dosage (g) . |
|---|---|---|
| R1/36/F | 42 | 15.7 |
| R2/58/F | 80 | 26.2 |
| R3/43/M | 32 | 15.7 |
| R4/54/F | 42 | 50.5 |
| R5/36/F | 55 | 277.0 |
| R6/30/F | 34 | 226.0 |
| R7/48/F | 71 | 418.7 |
| Patient no./age, y/sex . | Days to HCR . | Total As4S4 dosage (g) . |
|---|---|---|
| R1/36/F | 42 | 15.7 |
| R2/58/F | 80 | 26.2 |
| R3/43/M | 32 | 15.7 |
| R4/54/F | 42 | 50.5 |
| R5/36/F | 55 | 277.0 |
| R6/30/F | 34 | 226.0 |
| R7/48/F | 71 | 418.7 |
All patients with hematologic relapse were treated with all-trans-retinoic acid, chemotherapy, or both before treatment with As4S4.
For explanation of abbreviations, see Table 1.